{"id":"NCT00276380","sponsor":"Ipsen","briefTitle":"A Study on the Use of Tanakan® for Recovery of Neurological Impairment Following Ischaemic Stroke","officialTitle":"A Phase III, Multicentre, Randomised, Double-blinded, Parallel Group, Placebo Controlled Clinical Study for Evaluating the Efficacy of EGb 761® (Tanakan®) (240mg) in the Recovery of Neurological Impairment Following Ischemic Stroke","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2003-02","primaryCompletion":"2009-03","completion":"2009-03","firstPosted":"2006-01-13","resultsPosted":"2018-02-19","lastUpdate":"2019-01-08"},"enrollment":204,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Stroke, Acute","Neurological Impairment"],"interventions":[{"type":"DRUG","name":"EGb761","otherNames":["Tanakan"]},{"type":"DRUG","name":"Placebo","otherNames":[]},{"type":"DRUG","name":"Acetylsalicylic acid","otherNames":[]}],"arms":[{"label":"EGb761®","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"The purpose of this study is to evaluate the effectiveness of Tanakan® 240mg in association with Acetylsalicylic acid (325mg/day) in the recovery of neurological impairment following ischemic stroke.","primaryOutcome":{"measure":"Percentage of Subjects With Modified Rankin Score of Less Than 3 at the End of Study Period.","timeFrame":"Day 168","effectByArm":[{"arm":"EGb761®","deltaMin":59.8,"sd":null},{"arm":"Placebo","deltaMin":64.7,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"0.52"}]},"eligibility":{"minAge":"50 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":3,"exclusionCount":4},"locations":{"siteCount":10,"countries":["Czechia","Poland","Romania","Russia"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":12,"n":101},"commonTop":["Constipation","Insomnia","Cystitis","Headache","Arthralgia"]}}